Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism
|ClinicalTrials.gov Identifier: NCT02812888|
Recruitment Status : Unknown
Verified July 2016 by Hu Hao, The First People's Hospital of Xuzhou.
Recruitment status was: Recruiting
First Posted : June 24, 2016
Last Update Posted : July 6, 2016
Clustering of various metabolic parameters including abdominal obesity, hyperglycaemia, low high-density lipoprotein cholesterol, elevated triglycerides and hypertension have been used worldwide as metabolic syndrome to predict cardiometabolic risk. Thyroid dysfunction impacts on various levels of these components.
Recent evidence from HepG2 cells indicates that betatrophin, also known as TD26/RIFL/lipasin/ANGPTL8/C19orf80, a secreted protein that regulates glucose, lipid metabolism, and energy homeostasis, is induced by T3. However, the role of betatrophin in hyperthyroid patients is unknown.
The objective was to study serum betatrophin levels in hyperthyroid patients and the association of serum betatrophin levels with hyperthyroidism.
|Condition or disease||Intervention/treatment|
|Hyperthyroidism||Drug: thionamide treatment for 3 months|
Thyroid hormone (TH) is a critical hormone responsible for growth, development, and metabolism. It maintains basal metabolic rate (BMR), improves adaptive thermogenesis, and thus modulates body weight by fine-tuning energy expenditure and intake. Hyperthyroidism, a condition with excess TH, presents a status of negative energy balance that is characterized by weight loss, increased energy expenditure, and accelerated lipolysis and gluconeogenesis. The mechanism underlying hypermetabolic status in hyperthyroidism is complicated. In hyperthyroidism, excess TH promotes the metabolism rate primarily by binding to TH receptor α or β, and in turn by further influencing diverse metabolic pathways. Recent studies have revealed that TH signals were involved in cross talk with a range of other metabolic signaling pathways in different metabolic organs. In liver, TH interacts with peroxisome proliferator-activated receptor (PPAR) α, PPARγ, and liver X receptor α pathway; promotes fatty acid oxidation; decreases cholesterol; and enhances gluconeogenesis. The elements required for TH action are well documented, but understanding the interaction between TH and various pathways remains a challenge.
Betatrophin, also known as TD26/RIFL/lipasin/ANGPTL8/C19orf80, is a novel protein predominantly expressed in human liver. Increasing evidence has revealed associations between betatrophin expression, glycemia and serum lipid profiles, particularly in patients with obesity or diabetes. Stimulators of betatrophin, such as insulin, thyroid hormone, irisin, SIRT1 and caloric intake, are usually relevant to energy expenditure or thermogenesis. A previous report revealed that betatrophin mRNA is induced by the thyroid hormone in HepG2 cells. Subsequent studies confirmed that transcriptional regulation is dependent on the thyroid hormone receptor that binds to the betatrophin upstream element. Therefore, betatrophin is a novel gene dramatically activated by the thyroid hormone. However, there is no evidence to date showing that TH is capable of regulating betatrophin expression in human beings. The current study investigated the change of betatrophin levels in patients with hyperthyroidism before and after thionamide treatment and explored the association of serum betatrophin levels with hyperthyroidism.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||240 participants|
|Target Follow-Up Duration:||3 Months|
|Official Title:||Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism|
|Study Start Date :||July 2016|
|Estimated Primary Completion Date :||March 2017|
|Estimated Study Completion Date :||June 2017|
Patients with hyperthyroidism
Drug: thionamide treatment for 3 months
Hyperthyroid patients would received thionamide treatment (methimazole, propylthiouracil, or propranolol) for 3 months, and euthyroidism would be obtained.
Other Name: methimazole, propylthiouracil, or propranolol
Normal control subjects
- Serum betatrophin levels [ Time Frame: Change from baseline at 3 months ]
- Thyroid function index [ Time Frame: At baseline and at the end of the third month ]
- blood lipid profile [ Time Frame: At baseline and at the end of the third month ]
- liver function index [ Time Frame: At baseline and at the end of the third month ]
- hypersensitive c-reactive protein (hs-CRP) [ Time Frame: At baseline and at the end of the third month ]
- Blood glucose [ Time Frame: At baseline and at the end of the third month ]
- Serum insulin levels [ Time Frame: At baseline and at the end of the third month ]
Biospecimen Retention: Samples Without DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02812888
|Contact: Hu Hao, MD||+86 firstname.lastname@example.org|
|Contact: Wang Zhaoling, BD||+86 email@example.com|
|Study Chair:||Wang Zhaoling, BD||The First People's Hospital of Xuzhou|
|Study Director:||Hu Hao, MD||The First People's Hospital of Xuzhou|
|Principal Investigator:||Gao Zhaohua, MD||The First People's Hospital of Xuzhou|
|Principal Investigator:||Zhou Tingting, MD||The First People's Hospital of Xuzhou|
|Principal Investigator:||Yin Wenwen, MD||The First People's Hospital of Xuzhou|
|Principal Investigator:||Cai Ruonan, MD||The First People's Hospital of Xuzhou|